NanoViricides Platform Enables Rapid Development of Robust Nanomedicines Against Influenza and HIV
Company President Dr. Diwan Describes Technology and Pipeline at NanoBusiness 2009 Conference
Press Release
Source: NanoViricides, Inc.
On Monday September 14, 2009, 9:25 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Dr. Diwan described the salient features of nanoviricides technology. “Viruses can be fooled,” he said, adding, “We use their own smarts to attack them. The site at which a virus binds to the cell surface never changes, no matter how much the virus itself changes. We mimic this site, and the cell surface, so the virus particle can bind to the nanoviricide thinking it is binding to a cell. We anticipate very little escape mutation problem, if we do this successfully.”
He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (Tamiflu®, Roche), in lethal influenza virus challenge administered to mice. These studies have been repeated and the Company has performed SAR (structure-activity-relationship) studies to develop the best drug candidates against influenza. “Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”
He also described that HIVCide™ was found to be more than twenty-five times (25X or 2,500%) superior to the entire three drug HAART cocktail in a standard SCID-Hu mouse model study. The mice were treated with only 150 mg/kg of nanoviricides and this treatment both led to improvement in double-positive CD4+/CD8+ T cells and reduction in HIV-1 viral load that was equal to or slightly better than that in HAART-treated mice. The HAART treated mice received a total drug load of 4,200 mg/kg, indicating superior results with HIVCide. Moreover, HAART cocktail caused significant toxic effects, whereas the nanoviricides produced no clinical adverse signs in this study.
Dr. Diwan also described the high efficacy of EKCCide™ in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.
Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF™ “Accurate Drug In Field” technology against novel and emerging viruses.
“The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest,” said Dr. Eugene Seymour, MD, MPH, commenting further that, “We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.”
Press Release
Source: NanoViricides, Inc.
On Monday September 14, 2009, 9:25 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Dr. Diwan described the salient features of nanoviricides technology. “Viruses can be fooled,” he said, adding, “We use their own smarts to attack them. The site at which a virus binds to the cell surface never changes, no matter how much the virus itself changes. We mimic this site, and the cell surface, so the virus particle can bind to the nanoviricide thinking it is binding to a cell. We anticipate very little escape mutation problem, if we do this successfully.”
He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (Tamiflu®, Roche), in lethal influenza virus challenge administered to mice. These studies have been repeated and the Company has performed SAR (structure-activity-relationship) studies to develop the best drug candidates against influenza. “Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”
He also described that HIVCide™ was found to be more than twenty-five times (25X or 2,500%) superior to the entire three drug HAART cocktail in a standard SCID-Hu mouse model study. The mice were treated with only 150 mg/kg of nanoviricides and this treatment both led to improvement in double-positive CD4+/CD8+ T cells and reduction in HIV-1 viral load that was equal to or slightly better than that in HAART-treated mice. The HAART treated mice received a total drug load of 4,200 mg/kg, indicating superior results with HIVCide. Moreover, HAART cocktail caused significant toxic effects, whereas the nanoviricides produced no clinical adverse signs in this study.
Dr. Diwan also described the high efficacy of EKCCide™ in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.
Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF™ “Accurate Drug In Field” technology against novel and emerging viruses.
“The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest,” said Dr. Eugene Seymour, MD, MPH, commenting further that, “We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.”
14 comments:
Look for another dead cat bounce until announcement of a major pharma deal.
Then all hell will brak loose!
Allan,
Came across your blog this am while doing a bit of reading on NNVC, which I don't own any of. Nice site.
Btw, do you still live at Kiawah? Love the place! Great golf.
Jay
That was some synopsis of everything the past year. The only thing missing, and quite surprising to me, was any mention of HSV-1 and -2 from the last PR regarding results from Thevac.
It metions the other frugs "of very high commercial interest," but not that one. I guess in comparison a $2 billion market would be of less interest than eye drops at $5 billion, FluCide at $8 to $10 billion and HIV at $10 billion to $20 billion.
Word Origin & History
frug
1964, disco dance derived from the Twist, of unknown origin.
Online Etymology Dictionary, © 2001 Douglas Harper
Cite This Source
I know the f is next to the d on qwwerty, but it kinda works too.
PM
Nice PM, lol...
But PM? Isn't it QWERTY or do you just like "double U's" a lot? lol, ha ha ha .
lol...please stop...investing is an anxiety ridden exhausting sober undertaking.
Allan, Quick question, any chance of adding "spell check" as a feature on the posting page? Seems most all of us need it. All except you Allan. I have been reading and prospering at your blog for 4 years. I never once was able to catch you in a grammatical error or a spelling error. Anyone who doubts this claim is invited to read the AllAllan archives and prove me wrong. I'm worried about Allan? Seems you might not be enjoying enough single malt scotch like the rest of us AllAllan cowboys? lol.
Warmest regards from NYC, Joe
cvm hit 1.08 today. up big from when allan mentioned it hear.
rob g
Jay: I lived on Kiawah for 10 years, then met someone who stole me away from my family and beach, before the whole thing imploded, driving me to the edge, but arriving instead in the beautiful Arizona desert.
Dr. FG: I decided to leave this early morning blog up first above, instead of a new blog tonight. This may not be the blockbuster deal we are expecting, but it contains the first nuggets of our gold rush, let it seep in and note the shining rocks that remain in the pan.
Joe in NYC: Glenfiddich, 15 year, about $40/bottle but as smooth and mellow as 18 years' twice the price. As for my spelling and grammar, my MacBook Pro saves my behind most of the time, although I admit to some poetic license on occasion, where my words can have several meanings, i.e. is he talking about the age of his scotch or the age of his date?
With all due respect Rob G. It is here , not hear. Hear is when you hear the bell ring, here is the here and now when you are reading this polite instruction on the correct use of the English language. With that said , go CVM! Go AllAllan!
Joe,
Just for the challenge, Allan often uses the word then in place of than.
Allan - you are certainly doing us all a great service here. Any chance you can give us your current thoughts on where gold and silver are going near term? thanks.
I will get excited Allan when they start getting their IND together to launch a Phase I trial. I think that will be the bigger springboard.
Until then those exposed to NNVC should keep a responsible % of their portfolio invested, not the mother load.
Post a Comment